# Globus Medical, Inc. – Consensus ‘buy’ rating and 25.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/globus-medical-inc.consensus-buy-rating-and-25.2-upside-potential/4121129817
- Published: 2023-10-13T15:01:41+01:00
- Author: Charlotte Edwards

**Globus Medical, Inc.** with ticker code (GMED) now have 11 confirmed analysts 
covering the stock with the consensus suggesting a rating of ‘buy’. The target price
High/Low ranges between 77 and 58 and has a mean target at $66.36. Now with the 
previous closing price of $53.02 this would imply there is now a potential upside
of 25.2%. There is a 50 day moving average of $53.20 while the 200 day moving average
is $58.98. The company has a market cap of 7.44B. The stock price is currently at:
53.2 USD

 The potential market cap would be $9,307,291,877 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 26.73, revenue per share of 10.96
and a 7.51% return on assets.

Globus Medical, Inc. is a medical device company that develops and commercializes
healthcare solutions. The Company’s product categories include Musculoskeletal Solutions
and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable
devices, biologics, accessories, and surgical instruments used in a range of spinal,
orthopedic and neurosurgical procedures. Its spine products address the majority
of conditions affecting the spine, including degenerative conditions, deformity,
tumors, and trauma. It provides solutions that facilitate both open and minimally
invasive surgery (MIS) techniques. It includes traditional fusion implants, such
as pedicle screws and rod systems. Its orthopedic trauma solutions are designed 
to treat a variety of orthopedic fracture patterns and patient anatomies in the 
upper and lower extremities, as well as the hip. Enabling Technologies is comprised
of imaging, navigation and robotics (INR) solutions for assisted surgery.

Share on: